COPENHAGEN, Denmark, July 1, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces several key executive management changes to optimize value from its proprietary AI-Immunology™ platform and pipeline. Christian Kanstrup has stepped down as Chief Executive Officer (CEO) and Evaxion has initiated the search for a new permanent CEO to lead its next phase of growth and to accelerate value creation from its AI-based t ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the additional sale of approximately $3.4 million in aggregate principal amount of convertible promissory notes and accompanying warrants. Together with a prior sale of $2.3 million of convertible promissory notes and accompanying warrants, the Company raised an aggregate of $5.7 m ...

These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautione ...

Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on Oncternal's current ...

Financial Status and Strategy - CureVac has a strong financial position with €550.9 million in cash as of September 30, 2024, and an expected cash runway into 2028[82, 87] - The company streamlined costs and enhanced financial discipline, including a 30% workforce reduction expected by the end of 2024[8, 85, 88] - CureVac refocused its portfolio on innovation and R&D, concentrating on high-value programs in infectious diseases and oncology[8, 9] - A strategic transformation is on track, with OPEX expected to decrease by over 30% from 2025 onwards, including a €25 million decrease in personnel costs[85] Pipeline and Development - CureVac is advancing key pipeline milestones for novel medicines targeting unmet needs, with a focus on expanding the pipeline in oncology and infectious diseases[10, 14] - In oncology, a new shared-antigen lung cancer program is set to start clinical trials in H2 2025, and personalized cancer vaccines are progressing with the first candidate expected to enter the clinic in H2 2026[14] - For infectious diseases, a new non-respiratory program was initiated for Uropathogenic E coli (UPEC) in urinary tract infections, with promising preclinical data[14] - Respiratory infectious disease programs, including seasonal influenza, avian influenza, and COVID-19, are fully out-licensed to GSK, with Phase 3 starting for seasonal flu in 2025[13, 37, 86] Technology and Manufacturing - CureVac's mRNA platform is versatile, featuring precision mRNA backbone, improved LNP delivery systems, and a strong intellectual property portfolio[12, 13] - The company utilizes advanced delivery systems, including proprietary therapeutic area-specific next-generation lipid nanoparticles, and scalable manufacturing, including The RNA Printer®[12] - CureVac's Infectious Disease LNP offers thermostability for more than 12 months at refrigerator temperature (2-8°C)[60]

SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock. Nektar is selling 4,255,320 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $23.50 per share. The gross proceeds to Nektar from the offe ...

Corporate Presentation June 2025 2 Disclaimer BioAge Labs, Inc. (the "Company") does not (nor their respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation or any other written or oral information made available to any interested party or its advisors and any liability therefor ...

- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug As of December 31, 2024, the Company had audited cash and cash equivalents of US$85.2 million. The proceeds from the investment of Sanofi, together with the current cash and cash equivalents, are expected to be sufficient to fund planned operations into 2027. Following the equity investment and strategic collaborations, a Sanofi representative will join Adagene's Scientific Advisory Board ( ...

Genitourinary Tumor Study Ongoing with Active Screening and EnrollmentMILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme (TEM-GBM) study, with 25 patients receiving Temferon. Two patients have been enrolled in the TEM-LT long-term follow-up study, surviving three years from the time of 1st surgery. One of these long-term survivors has not exper ...

ARCT-810 Overview - Arcturus is a commercial mRNA medicines company with a pipeline of multiple therapeutic candidates in advanced clinical trial development[7] - ARCT-810 aims to restore OTC enzyme function, potentially preventing neurological damage and the need for liver transplantation in Ornithine Transcarbamylase (OTC) Deficiency patients[9] - ARCT-810 has received Orphan Drug Designation (FDA), Orphan Medicinal Product Designation (EMA), Fast Track Designation (FDA), and Rare Pediatric Disease Designation (FDA)[14, 15, 16, 17] Clinical Trial Results - European Phase 2 study (N = 8; 6 ARCT-810 / 2 placebo) is completed, and the U S Phase 2 study (N = 3 completed to date) is ongoing[20] - Combined analysis of both Phase 2 studies showed mean glutamine levels decreased significantly (N = 8, p-value = 0 0055)[25] - In the Phase 2 Open-label U S Study, mean glutamine levels decreased significantly (N = 3, p-value = 0 004), with all subjects achieving normal levels after three administrations[28] - Interim Phase 2 data from the U S Open Label Study (N = 3) showed a mean RUF (relative ureagenesis function) increase of +14 7% from baseline to 28 days post-fifth dose, from 29 0% (SD 9 1%) to 43 7% (SD 21 7%), which is statistically significant (p-value = 0 026)[31] Safety and Tolerability - ARCT-810 was generally safe and well-tolerated in Phase 2 studies at all tested dose levels, comprising 40 participants to date, including 20 OTC deficient participants[34, 35] KOL Insights - Glutamine rises earlier than ammonia in OTC deficiency and has lower variability, making it a reliable indicator of urea cycle stress[47] - 15N-Ureagenesis assay directly reflects cycle function, providing a clear readout of therapeutic efficacy[47]